2 A unifying feature of many neurodegenerative disorders is the accumulation of poly-ubiquitinated protein inclusions in dystrophic neurons, e.g. containing α-synuclein, which is suggestive of an insufficient proteasomal activity. We demonstrate that α-synuclein and 20S proteasom components colocalise in Lewy bodies and show that subunits from 20S proteasome particles, in contrast to subunits of the19S regulatory complex, bind efficiently to aggregated filamentous but not monomeric α-synuclein. Proteasome binding to insoluble α-synuclein filaments and soluble α-synuclein oligomers result in marked inhibition of its chymotrypsin-like hydrolytic activity through a non-competitive mechanism that is mimicked by model amyloid-Aβ peptide aggregates. Endogenous ligands of aggregated α-synuclein like heat shock protein 70 and glyceraldehyde-6-phosphate dehydrogenase bind filaments and inhibit their anti-proteasomal activity. The inhibitory effect of amyloid aggregates may thus be amenable to modulation by endogenous chaperones, and possibly accessible for (1). The poly-ubiquitination of proteins represents the result of the cellular system that recognises misfolded or unwanted proteins and tags them for degradation by the proteasome via the sequential action of three enzymes (for a recent review on the ubiquitin-proteasomal system, see 2). First the ubiquitin activating enzyme E1 activates ubiquitin in an ATP dependent process, after which the activated ubiquitin is passed onto the E2 class of ubiquitin conjugases. Then E3 ubiquitin ligases recognise the misfolded proteins and mediate covalent binding of ubiquitin to them. Normally, polyubiquitinated proteins are recognised by the 19S regulatory complex of the 26S proteasome that unfolds the substrates and feeds them to the 20S proteolytic core particle of the 26S proteasome. The proteasome comprises 3 hydrolytic activities; the trypsin-like, the chymotrypsin-like and the caspaselike hydrolytic activities that combined assure the complete degradation of substrates. Accumulation of ubiquitinated proteins is an indicator for an imbalance between the production and ubiquitin-labeling of misfolded proteins and the catabolic capacity of the proteasome.
INTRODUCTION
The development of polyubiquitin-containing intracellular inclusions in cell bodies and dystrophic neurites of nerve cells is a key feature of several neurodegenerative disorders e.g. in Alzheimer's disease (AD 1 ), Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Huntington's disease (1) . The poly-ubiquitination of proteins represents the result of the cellular system that recognises misfolded or unwanted proteins and tags them for degradation by the proteasome via the sequential action of three enzymes (for a recent review on the ubiquitin-proteasomal system, see 2). First the ubiquitin activating enzyme E1 activates ubiquitin in an ATP dependent process, after which the activated ubiquitin is passed onto the E2 class of ubiquitin conjugases. Then E3 ubiquitin ligases recognise the misfolded proteins and mediate covalent binding of ubiquitin to them. Normally, polyubiquitinated proteins are recognised by the 19S regulatory complex of the 26S proteasome that unfolds the substrates and feeds them to the 20S proteolytic core particle of the 26S proteasome. The proteasome comprises 3 hydrolytic activities; the trypsin-like, the chymotrypsin-like and the caspaselike hydrolytic activities that combined assure the complete degradation of substrates. Accumulation of ubiquitinated proteins is an indicator for an imbalance between the production and ubiquitin-labeling of misfolded proteins and the catabolic capacity of the proteasome.
A group of neurodegenerative disorders, e.g. PD and DLB, are characterised by the filamentous Lewy body-type of cytoplasmic inclusions in the degenerating cells (1) . Aggregates of misfolded α-synuclein (AS) form the filamentous core of the Lewy bodies and Lewy neurites (3) and the aggregates presumably play a role in the degeneration for more reasons. First, the association of missense mutations in AS with autosomal dominant PD evidences a direct gain of toxic function for AS in the degenerative process where the dopaminergic neurons of the substantia nigra preferentially are lost (4, 5) . Second, the pathogenic AS mutations, A30P and A53T increase AS propensity for aggregation (6, 7) . Likewise, aggregated insoluble AS has been demonstrated in tissue affected by 7
METHODS
Miscellaneous and proteins. All chemicals were of analytical grade if not otherwise stated. Thioflavin S and Congo Red were from Sigma (St. Louis, MO.). Human 20S proteasome was isolated from human erythrocytes by affinity chromatography on immobilised MCP21 monoclonal antibody (26) . The specific activities of the 20S proteasome were: chymotrypsin-like activity, 4.0 nmol/min/mg protein using Suc-Ala-Ala-Phe-7-amido-4-methyl-coumarine; trypsin-like activity, 5.1 nmol/min/mg protein using Z-Ala-Ala-Arg-7-amido-4-methyl-coumarine; caspase-like activity, 1.9 nmol/min/mg protein using Z-Leu-Leu-Glu-β-naphylamide. The Aβ-(1-40) peptide was from (Schaefer-N., Copenhagen Denmark). Recombinant human HSP70 was from Stressgen, (Victoria, B.C., Canada) and GAPDH from Sigma. Both GAPDH and HSP70 were centrifuged for 30 min at 120,000 rpm at 4˚C in a TLA 120.1 rotor in a Optima TLX centrifuge (Beckman Instruments) to remove any aggregated materials prior to pull-down experiments. Recombinant human full-length AS-(1-140), C-terminally truncated AS-(1-95) and β-synuclein were expressed in E. coli and purified as described previously (27, 28) , followed by an additional reverse phase HPLC purification step on a Jupiter C18 column (Phenomenex, CA) in 0.1% trifluoroacetic acid with an acetonitril gradient. The proteins were subsequently aliquoted, lyophilized and stored at -80 o C.
Primary antibodies. Sheep anti-AS was affinity purified as described (29) and obtained from Abcam, UK. Rabbit ASY-1 IgG was raised against full-length human recombinant AS (28) . Rabbit FILA-1 IgG, specific for aggregated AS, was prepared by immunising rabbits with sucrose density gradient purified AS-(1-140) filaments. The immune serum was subsequently passed several times through a column with immobilised AS. This assured the removal of all detectable immunoreactivity toward monomeric AS as determined by dot blotting. The serum lacking the monomer binding antibodies was then incubated with density gradient purified AS filaments and the aggregate-binding antibodies were by guest on November 17, 2017 http://www.jbc.org/ Downloaded from 8 isolated by gradient co-sedimentation with the filaments. The antibodies were subsequently eluted from the filaments by incubation in 100 mM glycine pH 2.5 followed by gradient centrifugation to separate the insoluble AS filaments from the FILA-1 IgG. The IgG was finally concentrated by protein A chromatography. The monoclonal antibodies, used to detect 20S proteasom subunits were: MCP72 (α7 subunit); MCP196 (α5 subunit); MCP20 (α6 subunit); MCP231 (α2, α3, α6, α7 subunits); MCP421 (β1 subunit) (30) . The monoclonal antibodies to subunits of the 19S regulatory proteasome complex were: p31-38 (S14/Rpn12 subunit); S5a-18 (S5a/Rpn10 subunit); TBP1-19 (S6´/Rpt5 subunit) (31) . A rabbit polyclonal antibody to S6'(Affinity Bioreagens) was also used. As were affinity purified rabbit anti-ubiqutin (Dako, Denmark) and monoclonal antibodies against HSP70 (clone BRM-22) and β-actin (both from Sigma, St. Louis, MO., USA).
Immunohistochemistry. Samples of substantia nigra from sporadic PD (n =4), DLB (n =3) and control subjects (n = 4) were obtained from the Netherlands Brain Bank (Amsterdam, the Netherlands) and fixed in 10 % neutral buffered formalin and embedded in paraffin. Control samples were obtained among patients without neurological disease and with no pathological changes in sections of the substantia nigra pars compacta (SNpc). The diagnosis of PD in the human autopsies was based on loss of neuromelanin pigment and excessive number of Lewy bodies in remaining SNpc neurons in eosin stained section. The paraffin sections were cut at 2 µm and subjected to immunohistochemistry as previously described (32) . Complementary sections were demelanized using successive incubations with 0.25 % potassium permanganate for 20 min followed by 1 % oxalic acid and 1 % potassium bisulfite for 4 min (33) . The sections were incubated overnight at 4 o C with polyclonal rabbit-antihuman ubiquitin diluted 1:500 (Dako, DK), sheep-anti-human AS diluted 1:200 (Abcam, UK), or antihuman 20S proteasome antibody MCP20. The sections were developed using 3,3-diaminobenzidine tetrahydrochloride as chromogen. To examine the extent of non-specific binding, non-immune sera was 9 substituted for the primary antibody. The relative ratio between the presence of AS and 20S proteasome in Lewy bodies was estimated by staining four pairs of sections per autopsy for AS and 20S proteasome, which were counted for their content of positive Lewy bodies.
Immunolabeling of isolated Lewy bodies. Immunohistochemical staining was conducted in isolated
Lewy bodies from fresh frozen brains of patients with DLB. The cingulate cortex from 5 DLB cases were analysed. The isolation procedure was modified from (28, 29, 34) with the Lewy body smears prepared by washing the Lewy body enriched fraction 3 times in Tris-buffered saline (TBS, 0.1M TrisHCl, 0.9% NaCl, 5 mM EDTA, and protease inhibitors) followed by smearing on gelatine-coated glass slides and air-drying for 2 hours at room temperature. The smears were fixed in 4% formaldehyde in TBS for 10 minutes, and then incubated with 3% H 2 O 2 in 50% methanol-TBS for 10 minutes to bleach endogenous peroxidase activity. Following 3 x 5 minutes rinse in TBS, the smears were blocked with 20% normal horse serum for 30 minutes, and then incubated for 60 minutes in primary antibody solution containing monoclonal antibody MCP72 (1:300), or MCP196 (1:300). To facilitate recognizing Lewy bodies, the primary antibody solution also included sheep anti-AS (1:300), or antiubiquitin (1:300). The smears were rinsed 3 times in TBS, then labeled for 60 minutes with Cy2 conjugated donkey anti-mouse IgG, in combination with Cy3 conjugated donkey anti-sheep IgG or Cy3 conjugated anti-rabbit IgG (all used 1:100 dilution, all from Jackson ImmunoResearch Labs Inc, PA, USA). The primary and secondary antibody dilutions used above were predetermined by serial titrations before formal experiments. Controls for antibody specificity included omitting primary or secondary antibodies, and preabsorption the primary antibody with ubiquitin or AS. Lewy body staining was not detected in these control experiments. The smears were examined using a Bio-Rad confocal laser scanning microscope and software package (Bio-Rad MRC 1024, Richmond, CA, USA) by guest on November 17, 2017 http://www.jbc.org/ Downloaded from (34) with the scanned image representing an approximately 1µm thick slice through the centre or equatorial plane of the Lewy body.
Preparation of AS aggregates. AS aggregates were made by resuspending lyophilised AS in 20 mM Tris, 150 mM NaCl, pH 7.5, 0.02% NaN 3 at 7 mg/ml followed the ultracentrifugation to remove insoluble aggregates (28) . Incubation of β-synuclein (5.5 mg/ml) and Aβ-(1-40) peptide (4mg/ml) was performed by analogous procedures. The supernatant was incubated at 37 o C on a shaker for approximately 14 days. Insoluble AS aggregates were isolated for proteasome activity assays and electronmicroscopy by sedimentation through a 40% sucrose cushion (28) followed by resuspension in the buffer of choice. Soluble AS aggregates were isolated by gelfiltration of the soluble supernatant, obtained after ultracentrifugation of the aggregated AS sample, on a 24 x 1 cm Biogel A 1.5 M column (Biorad) in 150 mM NaCl, 10 mM NaH 2 PO 4 , pH 7.4 (PBS) at 0.5 ml/min. The buffer was changed to 1 M Hepes, pH 8.0 when isolating soluble oligomers for the proteasome activity assay. The elution of the aggregated oligomers was determined by dot-blotting of the eluted fractions using the FILA-1 antibody and the total AS was monitored by probing the membrane with the ASY-1 antibody.
Electron microscopy. Electron microscopy was used to analyse the insoluble AS filaments and to visualize the binding of purified 20S proteasomes to the filaments. Filaments isolated from 30 µl aggregated AS (7mg/ml) were resuspended in 30 µl PBS supplemented 20 mM NaN 3 after pelleting through the sucrose cushion as described above. Purified 20S proteasome was centrifuged for 10 min at 100,000 rpm at 4˚C in a TLA 120.1 rotor in a Optima TLX centrifuge (Beckman Instruments) to remove aggregated materials. Soluble 20S proteasome (40 µl at 0.18 mg/ml) was incubated together with 5 µl resuspended AS filaments (5mg/ml) for 2h at 25˚C. Non-bound proteasome was removed by sucrose gradient centrifugation of the filaments with bound 20S proteasome. The sedimented filaments 11 with attached 20S proteasome was resuspended in 70 µl of distilled water. As a control was used filaments not incubated with 20S proteasomes before the centrifugation and soluble 20S proteasomes diluted to 0.16 mg/ml in PBS before direct application to the grid. All samples were pipetted onto carbon-coated nickel grids (3 µl for each grid) and allowed to stand for 2 min. The samples were stained with 1% aqueous uranyl acetate for 1 min. The grids were then air-dried, examined in a Morgagni 268, 80kV electron microscope and photographs were taken at 14,000, 18,000 or 22,000 times magnification.
For immuno-gold labelling, grids with samples were blocked with blocking buffer (PBS with 0.05 M glycine and 0.1% milk protein), for 10 min and incubated with the primary antibody MCP72 (0.07 mg/ml) for 1h. The grids were then washed three times for 5 min with blocking buffer and then incubated with goat anti-rabbit IgG conjugated to 5 nm diameter gold particles (Amersham) diluted 1:100 in PBS with 1% fish gelatin, 0.06% polyethylenglycol and 0.1% milk protein for 1 h. The grids were then washed twice for 5 min in PBS with 0.1% milk protein and then twice for 5 min in water. The grids were finally stained and examined as the non-immunolabeled samples.
Filament pull-down assay.
Cellular cytosol was prepared from primary cultures of normal human skin fibroblasts (Rattan 1998) and from rat brain (36) . Cells, at confluence, were trypsinized and collected by centrifugation (1000× g, 10 min, 4° C). The cells were sonicated in 50 mM NaCl, 10 mM HEPES pH 8, 0.5 M sucrose, 1 mM EDTA, 0.2% (v/v) Triton X 100, 0.2 mM phenylmethanesulfonyl fluoride, 0.05% β-mercaptoethanol The filament pull-down assay was performed by placing the protein samples on a cushion of 1.6 ml 40% sucrose, 13 mM MES and 1 mM EDTA, pH 7.0 followed by centrifugation at 55,000 rpm for 30 min in a TLS 55 swing out rotor at 4°C in a Optima TLX centrifuge (Beckman Instruments). The pellets were either recovered for the proteasome assay by resuspension in 1M HEPES pH 8.0 or solubilised in 30 µl 8 M urea with 4% SDS for 16h in 37°C. The latter to ensure complete depolymerisation of the filaments. Non-bound proteins, remaining in the supernatant, were analysed by the precipitation of 500 µl of the supernatant in trichloroacetic acid. The solubilised pellets and the precipitated supernatants were dissolved in DTE-containing SDS-polyacrylamide gel electrophoresis (PAGE) loading buffer, heated 95°C for 3 min and subjected to SDS-PAGE followed by analysis with staining of the gel by silver or Coomassie blue or by immunoblotting (28) .
Proteasome assay. Approximately 80% confluent fibroblasts were scraped of into 100 mM Tris/HCl buffer, pH 7.5 (1ml per 75 cm 13 10 min at 4°C. For the proteasome assay, the cytosol was used at a concentration of 100 µg protein/ml and the purified human erythrocyte 20S proteasome at a concentration of 2 µg protein/ml. The hydrolytic activity for the chymotrypsin-like, trypsin-like and caspase-like hydrolytic activities were determined as previously described (37) . The coefficient of variation for the proteasome assay ranged from 0.8 -6.3% in 6 independent experiments with the mean being 3%. Proteasome enzyme activities were calculated as the difference in activity measured in the absence and in the presence of the proteasome inhibitor, lactacystin and in some experiments the peptide aldehyde Cbz-Leu-Leu-Leucinal (MG132), both being potent inhibitors of primarily of the chymotrypsin-like activity. All the activity measurements were done in duplicates or triplicates from independent samples, as stated in the legends.
Fluorescence of cleavage products from peptide substrate was measured on a Kontron SFM 25 spectrofluorometer. The effect of aggregated and non-aggregated AS on the proteasomal activity was determined by incubating proteasomes with AS for 60 min at 37 o C prior to the addition of the fluorogenic substrate.
RESULTS

Localisation of 20S components in Lewy bodies
Lewy bodies denote the characteristic inclusion bodies of PD and DLB (38); they contain abundant ubiquitinated material indicative of an insufficient proteasomal function (Fig. 1, panel A) . AS in a filamentous form comprise a main component of Lewy bodies (Fig. 1, panel B; 39 ). 20S proteasomes were observed in the cytoplasm of both control and brain disease cases and the α6 subunit specific antibody MCP20 also labeled Lewy bodies of both PD and DLB cases ( specific for 20S proteasomal α5 and α7 subunits. There was no obvious difference in the number or intensity of the labeled Lewy bodies between the two antibodies. In general, both the ubiquitin and proteasome antibodies labeled the peripheral portion of Lewy bodies more intensely where the AS immunoreactivity was also most intense ( Fig. 1, lower panel) . Compared to that of ubiquitin, the labeling of proteasome subunits appeared punctately or granularly, and often extended further towards the cental core of the Lewy bodies. Furthermore, while all Lewy neurites were also ubiquitin positive, they were rarely labeled by the proteasome specific antibodies (not shown). A similar co-localisation was noted in AS positive filamentous inclusions in astrocytes, isolated from brain tissue affected by multiple system atrophy (Gai and Jensen, data not shown).
Direct interaction between AS filaments and 20S proteasome particles
The co-localisation of 20S proteasomes and AS in the Lewy bodies provides a topological frame for an interaction between the two molecular species. To examine a putative direct interaction between AS filaments and proteasome we employed an AS filament binding-assay based on the use of filaments formed from recombinant human AS ( Fig. 2A, D) , which serve as bait for proteasomes in human fibroblasts cytosol. These filaments were readily depolymerised prior to SDS-PAGE by over night incubation in 8 M urea, 4% SDS, as demonstrated in the lanes with pelleted filaments ( Fig. 2A ). This contrast to the AS aggregates previously used by Snyder et al. (24) and demonstrates the aggregates are devoid of uncharacterised covalent modifications e.g. by oxidative crosslinks. Evidently, a range of cytosolic proteins was bound to the filaments as demonstrated by their presence in the pellet only when co-incubated with the filaments (Fig. 2A) . The presence of putative proteasomal proteins were investigated by immunoblotting using monoclonal antibodies; the subunits S6´/Rpt5 and S14/Rpn12 from the 19S regulatory complex were dectected in the cytosol as were the subunits α2, α3, α6, α7 and β1 subunits from the 20S proteasome core (Fig. 2, panel B) . Densitometric analysis of the blots showed that 5-10% of the subunits from 20S proteasomes in the cytosolic input were bound to the filaments. In contrast, a negligible binding was found for the 19S regulatory complex subunits S6`/Rpt5 and S14/Rpn12 although a faint band of both epitopes could be discerned. The S6' antibody in Fig. 2B , top panel was used by Snyder et al. (24) . The 19S regulatory complex can dissociate into two subcomplexes, the lid and the base (40) . S6´/Rpt5 is found in the base whereas S14/Rpn12 is a component of the lid. Thus, neither lid nor base binds avidly to AS filaments.
We next examined the direct interaction between AS filaments and human 20S proteasome particles, (Fig. 2D, panels 5,6 ).
It was of pivotal importance to determine if the interaction could represent a novel function of aggregated AS. Addition of up to an 8-fold excess of monomeric non-fibrillar AS had no detrimental effect on the co-sedimentation of purified 20S proteasome particles with the filaments, thus supporting a filament selectivity of the binding (Fig. 2E) . Similar data was obtained using proteasomes in cytosolic extracts (data not shown). Hence, proteasomal subunits co-localise with AS in Lewy bodies, and 20S proteasomes bind directly to AS filaments without the need for auxiliary cytosolic components in this reaction, which represents an apparent novel function of AS developed upon aggregation.
AS filaments selectively inhibit the chymotrypsin-like activity of the 20S proteasome
The possible functional consequences of the interaction between AS filaments and the proteasome were determined by measuring the ubiquitin-independent hydrolytic activity of the proteasome in human fibroblasts cytosol and in purified 20S proteasomes isolated from human erythrocytes. The assay uses small fluorogenic substrates for the individual hydrolytic activities of the 20S proteasome; the caspaselike, the chymotrypsin-like and the trypsin-like activity. The fluorescence in the presence of the proteasomal inhibitor lactacystin was subtracted as background in the assays shown in Fig. 3A . Similar background was obtained with the proteasome inhibitor MG132 and this inhibitor was used in subsequent analyses. Fig. 3A compares the effect on the individual hydrolytic activities of supplementing cytosolic proteasome and purified 20S proteasome with 10 nM monomeric and filamentous AS and demonstrates a strong inhibition of the chymotrypsin-like activity by aggregated but not monomeric AS. Noticeable, the effect on the individual activities in the cytosol and in the purified 20S proteasome is highly similar with i) a strong filament selective inhibition of the chymotrypsin-like activity, ii) the trypsin-like activity being marginally inhibited by both monomeric and filamentous AS and iii) the caspase-like activity being hardly affected. The molar concentration of the filaments cannot be expressed precisely due to their heterogeneous homopolymeric nature. We expressed their concentration by their monomeric AS building blocks well aware the actual concentration of the individual filaments is several fold lower than the concentration of their individual subunits. By this approach, IC 50 for the chymotrypsin-like activity with filaments was a more than 10 3 fold lower than with monomeric AS and corresponded to 0.5 nM, expressed as the equivalent of monomeric AS (Fig. 3B ). This means that the selectivity on a molar basis is even more pronounced and likely in the range10 5 -10 6 given that filaments are aggregates of 100-1000 monomers. The saturation curves for unpurified cytosolic proteasomes and purified 20S proteasome for the inhibition by monomeric and aggregated AS are nearly identical. The dose curve for the inhibition of the chymotrypsin-like activity by the proteasome inhibitor MG132 demonstrates an approximately 10 fold lower potency as compared to the AS filaments, based on their monomeric concentration, and thus underscores the toxic potential of AS unleashed upon conversion into filaments (Fig. 3B) . The mode of inhibition by AS filaments was investigated by measuring the rate of chymotrypsin-like catalysis at different substrate concentrations in the absence or presence of filaments. AS filaments inhibit the V max (Fig. 3C ), thus demonstrating a non-competitive mode of inhibition. The reduction of the V max displayed a dose-dependent correlation to the concentration of the AS filaments (data not shown). The by guest on November 17, 2017 http://www.jbc.org/ Downloaded from similar inhibitory pattern and saturation curves of the isolated 20S proteasome and cytosolic proteasomes indicate a similar inhibitory mode by the aggregated AS that likely is mediated by a direct effect on the 20S catalytic particle.
Amyloid-like characteristics are responsible for the 20S proteasomal inhibition by AS filaments
The structural characteristics of the aggregates responsible for the proteasomal inhibition were investigated by antibodies, filaments assembled from C-terminally truncated AS and Thioflavin-S that targets amyloid-structures (Fig. 4B) . The FILA-1 antibody is specific for the filamentous form of AS by more than 10 3 fold as compared to monomeric AS (Fig. 4A ). This antibody abrogated the inhibitory activity of the AS filaments just as potently as the ASY-1 antibody, raised against full length AS, thus strengthening the requirement for a structural transition of the AS (Fig. 4B) . The FILA-1 antibody bound only poorly to isolated Lewy bodies or to tissue investigated by immunohistochemistry (data not shown). This is likely due to the coating of the α-synuclein core fibrils by cytosolic proteins (41) . The aggregation of AS depends on structural determinants within its N-terminal 2/3, and this allowed for the formation of filaments by the C-terminal truncated AS-(1-95) peptides. A similar potency was observed of filaments formed from full length AS-(1-140) and AS-(1-95) (Fig. 4B) . AS filaments exhibit characteristics of the β-pleated structures present in amyloid-type filaments that can be targeted by Thioflavin-S. Preincubation of the AS filaments with Thioflavin-S, prior to their density gradient purification, inhibited their chymotrypsin-like inhibitory activity by about 60% without solubilising the aggregates (Fig. 4B) . This underscores the requirement for amyloid-like structures in the proteasomal inhibition by AS filaments, which were further corroborated by the potent proteasomal inhibition by the model amyloid filaments assembled from synthetic Aβ-(1-40) peptide (Fig. 4B) . Accordingly, the chymotrypsin-like inhibitory activity depends on amyloid-like structural elements that evolve during the development of AS filaments.
Soluble amyloid-like AS oligomers inhibit the 20S proteasome
Strategies aiming at abrogating filament formation can increase the content of oligomeric AS (42) .
Therefore, it is a question of considerable interest whether the detrimental effect of AS aggregates is due to the end-state of insoluble filamentous forms or whether soluble oligomers can partake in the inhibitory process. AS oligomers were isolated by subjecting samples of aggregated AS to ultracentrifugation to remove insoluble aggregates, followed by the separation of the soluble AS species by gelfiltration. Soluble oligomers, reacting with the filament specific antibody FILA-1, eluted from the column corresponding to molecular size markers larger than 150 kDA when aggregated AS was used as starting material (Fig. 5A, upper panel) . The neoepitope, formed when AS monomers polymerise, is therefore shared by insoluble filaments and soluble oligomers. No detectable FILA-1, but only ASY-1 immunoreactivity was present if non-aggregated AS was analysed by gel filtration albeit some of these ASY-1 positive structures likely represents AS multimers (Fig. 5A, lower panel) .
The soluble FILA-1 positive AS aggregates inhibited the proteasomal chymotrypsin-like activity, and this inhibition could be dose-dependly neutralised by FILA-1 IgG (Fig. 5B) . These oligomers likely contains β-pleated amyloid-like characteristics as preincubation with 2.5 mM Congo Red abrogated their inhitory activity (Fig. 5B) . Congo Red is able to disrupt preformed amyloid-type oligomers (43) .
The development of proteasomal inhibitory activity during the course of AS aggregation was compared to the development of insoluble aggregates to determine if soluble AS oligomers could play a significant role. The initial rate of development of proteasome inhibitory activity was rapid with a 50% of the maximal inhibition reached within 1-2 days where after the rate declined, although the inhibition continued to increase during the 14-day period (Fig. 6A) . This contrasted the development of insoluble AS aggregates that are first detectable after 6 days on Coomassie blue stained gels (Fig. 6B ).
β-synuclein was used as negative control for these experiments, because it is unable to form filaments (44) . Incubation of this control protein neither developed proteasome inhibitory activity nor insoluble aggregates (Fig. 6A, B) .
The pathogenic AS mutations A30P and A53T has been reported to enhance AS filamentformation although the process at neutral pH and at the concentrations used in the present study takes several days (45) . Of special interest was the observation that the A30P mutation specifically acted by increasing the formation of oligomers (45) . Fig. 6C demonstrates the faster development of proteasomal inhibitory activity in incubates of the A30P mutant as compared to the wild type and A53T mutant. Hence, the proteasome inhibitory activity of a given AS sample cannot simply be determined by assessing the amount of insoluble AS but may be more optimally reflected by the amount of FILA-1 immunoreactivity.
HSP70 and GAPDH attenuate the proteasomal toxicity of AS filaments.
HSP70 and GAPDH were discovered as AS-filament binding proteins in our search for brain proteins that selectively bind to aggregated AS (data not shown). The direct interaction of isolated GAPDH and HSP70 with insoluble AS filaments is demonstrated in Fig. 7A and 7B. HSP70 is of special interest as it attenuates the toxicity of AS and the amyloid-like polyglutamine peptides in transgenic Drosophila models of PD and Huntingtons disease (25, 46) . Recombinant HSP70 reverted the inhibitory effect of insoluble AS filaments on the chymotrypsin-like activity (Fig. 7C) . In PD, GAPDH was reported to relocate from the cytoplasm to Lewy bodies and the nucleus (47) . Co-incubation of GAPDH with the AS aggregates completely reverted the inhibitory effects on the chymotrypsin-like activity (Fig. 7C) .
Accordingly, endogenous proteins carry the potential for modulating the toxic properties of aggregated AS.
Heat shock treatment is known to induce the expression of various chaperones that assist the cell in combating unfolded protein stress (47) . Cytosolic proteasomes extracted from fibroblast cells by guest on November 17, 2017 http://www.jbc.org/ Downloaded from 21 after heat shock were more resistant to AS filaments than non-treated controls. HSP70 may participate in this protection as its expression was increased in this cytosol (Fig. 7D, inset) 
DISCUSSION
This report describes a mechanistic link between two hallmarks of the neurodegenerative disorders PD, DLB, Lewy body variant of PD and multiple system atrophy, namely the presence of aggregated AS and the accumulation of polyubiquitinated proteins. The latter likely being due to an insufficient proteasomal activity (17) . The functional link is the highly increased proteasome inhibitory activity that is developed upon aggregation of AS from its monomeric conformer. The increased inhibitory activity is selective toward the ubiquitin-independent proteasomal chymotrypsin-like activity in both human fibroblast cytosol and isolated human 20S proteasomes. By contrast, there is only a minor effect of AS on the trypsin-like and caspase-like hydrolytic activities and these effects do not depend on the aggregative state of AS. Interestingly, the chymotrypsin-like activity is far more important for degradation of proteins than are the trypsin-like-and caspase-like activities (48) . The trypsin-like inhibition had an IC 50 about 1 nM, so AS filaments are more potent than the proteasomal inhibitor MG132. This is in agreement with recent data on the AS inhibitory effect on HEK 293 cell extracts and the ubiquitin-dependent degradation by 26S proteasomes in rabbit reticulocyte lysates (24) . The neutralisation of the inhibition by the FILA-1 antibody, which selectively binds to aggregated AS, corroborates the need for an aggregation-dependent structural change. This inhibitory activity depends on structures related to amyloid-type aggregates, as demonstrated by the similar inhibition by Aβ-(1-40) aggregates. However, it does not require the aggregates to be in the insoluble filamentous state but merely requires a structural transition to a form present on both filaments and soluble oligomers, a transition that correlate to emergence of the epitopes recognised by the FILA-1 antibody. The inhibitory mode is non-competitive and thus resembles the inhibitory effect by HSP-90 (49) . It likely represents a structure change by the binding of the aggregated AS to the exterior of the β5 subunit, responsible for the chymotrypsin-like activity, and relayed to its catalytic site on its interior surface of the proteasomal barrel. This would be analogous to the effect of binding of monoclonal antibodies to the 20S proteasome (50) . Alternatively, the effect might be allosteric by binding to another subunit that subsequently changes the β5 subunit but this is less likely as the trypsin-like and caspase-like activities hardly were affected. discrepancy. First, the purified 20S proteasome Snyder et al. (24) was from a commercial source and purified by ammonium sulphate precipitation and several chromatographic steps. In contrast, the 20S proteasome preparation used in the present study was isolated by a milder procedure involving immuno-affinity chromatography (26) . We have experienced with one batch of purified 20S proteasome stored for prolonged time at -20 o C, that it lost the majority of its hydrolytic activity.
However, the remaining lactacystin-inhibitable chymotrypsin-like activity was not well inhibited by aggregated AS (data not shown). In this context, it is also reassuring that we got similar results with purified proteasomes and cell extracts.
Another reason for the discrepancy could be the different state of the aggregated AS. The material used in this study contains filaments, as demonstrated by electron microscopy (Fig. 2) , and it can be readily depolymerised to the native monomeric AS as seen by SDS-PAGE (Fig. 2) . By contrast, the AS used by Snyder (24) was a hexa-histidine fusionprotein incubated at an unspecified proteinconcentration and in an unspecified buffer and the aggregates formed was very old and not depolymerised by SDS treatment. Hence, the latter material could contain uncharacterised modifications e.g. oxidative crosslinks. However, the differences of the aggregates are likely of less importance as similar effects of aggregated AS on the cytosolic proteasomal activity was measured in the two reports. Our data support the interpretation of a direct effect of aggregated AS on the 20S proteasome particle because of the similar inhibitory profile on the individual proteasomal hydrolytic activities and the identical chymotrypsin-like inhibitory potency on purified 20S proteasome and cytosolic proteasomes. This is further corroborated by the demonstration of a direct binding of isolated 20S proteasomes to AS filaments.
The inhibitory effect on the 20S proteasome does not exclude an interaction with subunits in the 19S regulatory complex as reported for the S6´/Rpt5 (24) . However, the reported binding of the S6´/Rpt5 subunit was not selective to AS in its aggregated state and the efficiency of the binding was Fig. 6A; 52) . The process of oligomer formation is not yet clear but it is stimulated by the A30P mutation (45) and oxidative conjugation of dopamine to AS (42) . Our demonstration of a faster development of proteasome inhibitory activity in the A30P mutant (Fig. 6C) , as compared to the A53T and the wild type AS, is thus compatible with biochemical experiments on aggregation (45) . However, a comparison between different experiments on oligomerformation has to be exerted with great care, as the formation of these species is extremely sensitive to the protein concentration. Lashuel (52) demonstrated they can develop in less than one hour at AS concentrations of between 300-700 µM which is in the range of the current experiments. Importantly, we demonstrate that endogenous ligands carry the potential of attenuating the proteasomal inhibition by AS aggregates as shown for HSP70 and GAPDH. The HSP70-mediated rescue of proteasomal function from AS toxicity may be the reason for its cytoprotective effects in vivo when co-expressed with AS in Drosophila (25) and likely forms the basis for the protective effect of heat shock treatment on the proteasomal sensitivity to AS aggregates (Fig. 7) . GAPDH is considered as a household enzyme in the glycolytic pathway but accumulating data support it may partake nonby guest on November 17, 2017 http://www.jbc.org/ Downloaded from 27 glycolytic processes (47) . Its relocalisation into the nucleus and Lewy bodies in PD (54) suggest it may be sequestered and rendered unable to form its protective function against aggregated AS species in the cytosol. However, the current data does not allow unambiguously stating that the direct binding of GAPDH and HSP-70 to the AS aggregates causes the attenuation of the inhibition. A binding of GAPDH and HSP-70 to the 20S proteasome could in principle also cause the effect. Solving this issue will require additional experimentation e.g. with the identification of GAPDH mutants that fail to bind to the filaments. β-synuclein may represent another factor that modulates the AS toxicity, because it is able to bind AS and inhibit its aggregation, and because the co-expression of AS and β-synuclein leads to an attenuation of the pathology observed in AS single transgenic mice (55) .
The amyloid-type characteristics are important for proteasomal inhibition, as demonstrated by the effects of Congo Red and Thioflavin-S on the inhibitory effect of AS aggregates, and the inhibitory effects of amyloid filaments of the Aβ peptide, raise the following hypothesis.
Diseases characterised by intracellular amyloid-type filaments are subject to an inhibition of the chymotrypsin-like proteasomal activity, which contributes to the accumulation of polyubiquitinated proteins and a general degeneration of the cellular homeostasis via an impaired protein catabolism.
Such inhibition of the chymotrypsin-like activity has been reported in substantia nigral tissue affected by PD and DLB (16, 20) . The cellular selectivity of the neurodegeneration displayed by specific aggregating proteins, as observed in e.g. striatal neurons in Huntington's disease (1), contrast the oftenwider expression of the proteins. This may be due to a cell specific expression of the attenuating proteins. The latter binds to protein-specific structures in the aggregating proteins that are different from the common amyloid structures and hereby revert the toxicity, as exemplified by HSP70 and GAPDH. This hypothesis is corroborated by the demonstration of in vivo proteasome inhibitory properties of aggregates of glutamine expanded huntingtin peptides (56) that can be attenuated by 
